INOVIO PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
INOVIO PHARMACEUTICALS, INC. (INO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $768.44 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $768.44K, a 7.95% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $698.74K, a 50.07% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $757.09K, a 38.94% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $834.79K, a 44.86% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $3.76M, a 43.05% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.60M, a 40.44% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.07M, a 50.91% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $22.56M, a 14.36% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $768.44K 10-Q · filed 2026-08-12 | $1.47M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $698.74K 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $3.76M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $757.09K 10-Q · filed 2025-11-10 | $1.59M derived: sum of 2 quarters · filed 2026-08-12 | $2.99M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $834.79K 10-Q · filed 2026-08-12 | $2.23M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $1.40M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $6.60M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $1.24M 10-Q · filed 2025-11-10 | $2.75M derived: sum of 2 quarters · filed 2025-11-10 | $5.28M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $1.51M 10-Q · filed 2025-11-10 | $4.04M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.53M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $11.07M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $2.08M 10-Q · filed 2024-11-14 | $5.00M derived: sum of 2 quarters · filed 2024-11-14 | $8.81M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $2.92M 10-Q · filed 2024-11-14 | $6.73M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $3.81M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $22.56M 10-K · filed 2024-03-06 | |||
| 2022-09-30 | $3.23M 10-Q · filed 2023-11-09 | $11.57M derived: sum of 2 quarters · filed 2023-11-09 | $19.28M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $8.34M 10-Q · filed 2023-11-09 | $16.05M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $7.71M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $26.34M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | $5.62M 10-Q · filed 2022-11-08 | $11.27M derived: sum of 2 quarters · filed 2022-11-08 | $20.86M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $5.65M 10-Q · filed 2022-11-08 | $15.24M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $9.60M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $15.65M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $4.16M 10-Q · filed 2021-11-09 | $7.82M derived: sum of 2 quarters · filed 2021-11-09 | $11.82M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $3.66M 10-Q · filed 2021-11-09 | $7.66M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $4.00M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $10.90M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.08M 10-Q · filed 2020-11-09 | $5.44M derived: sum of 2 quarters · filed 2020-11-09 | $8.87M derived: sum of 3 quarters · filed 2020-11-09 | |
| 2019-06-30 | $3.36M 10-Q · filed 2020-11-09 | $6.79M derived: sum of 2 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $3.43M 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | $10.65M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $2.35M 10-Q · filed 2019-11-12 | $4.94M derived: sum of 2 quarters · filed 2019-11-12 | $8.52M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $2.59M 10-Q · filed 2019-11-12 | $6.16M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $3.58M 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $13.07M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $10.48M 10-K · filed 2019-03-12 | |||
| 2015-12-31 | $6.19M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |